3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
8
Lymphoma, T-Cell, Cutaneous
6
Waldenstrom Macroglobulinemia
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Anaplastic
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Lymphoma, B-Cell, Marginal Zone
4
Lymphoma
4
Immunoblastic Lymphadenopathy
4
Sezary Syndrome
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms, Plasma Cell
3
Mycosis Fungoides
3
Multiple Myeloma
3
Hodgkin Disease
3
Burkitt Lymphoma
3
Somatostatinoma
2
Skin Neoplasms
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Extranodal NK-T-Cell
2
Insulinoma
2
Glucagonoma
2
Carcinoma, Merkel Cell
2
Carcinoma, Medullary
2
Zollinger-Ellison Syndrome
1
Interventions
cemiplimab
3
Transdermal Patch
1
Sirolimus
1
Prednisone
1
Everolimus
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cutaneous Squamous Cell Carcinoma
×
Everolimus
×
Dermatologic
×
Clear all
NCT04339062
2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2
Completed
12 enrolled
13 charts